Less than half of new cancer therapies extend patient survival, Spanish study finds

Spanish researchers have completed a sobering audit of cancer medicine over the past dozen years, and the numbers tell a story of modest progress wrapped in escalating costs. Between 2010 and the time of the study, pharmaceutical companies brought seventy-three new cancer molecules to market with a combined 197 different applications against solid tumors. When researchers from Spanish hospital pharmacies examined what these treatments actually delivered, they found that fewer than four in ten drugs—just 43.7 percent—extended how long patients lived. Barely half showed what oncologists would call meaningful clinical benefit. And only one in ten made life meaningfully better for the people taking them.

The findings, published in The European Journal of Health Economics, expose a widening gap between the price tags on new cancer drugs and what they accomplish. Cancer kills 1.3 million Europeans annually, a figure that has barely budged despite pharmaceutical spending that has climbed steeply. The median survival gain across all these new therapies amounts to just 4.5 months over twelve years—a number that becomes harder to defend when a single course of treatment can cost hundreds of thousands of euros. The research team, led by Pelayo Nieto from the Hospital Santa Bárbara in Puertollano, used the European Society for Medical Oncology's clinical benefit scale to measure each drug's actual impact. The scale runs from one to five, with five meaning a drug extends both survival and quality of life. Most treatments clustered in the middle—scoring threes and fours—meaning they sit right on the borderline of what counts as genuinely helpful.

Beatriz González López-Valcárcel, a health economist at the University of Las Palmas de Gran Canaria and one of Spain's leading voices in the field, framed the implications plainly: the clinical gains are generally small, and the findings underscore how urgently Spain needs better systems to identify which treatments actually deserve public funding. The study's second finding offered some reassurance. When researchers checked whether Spain's Health Ministry aligned its funding decisions with clinical benefit, they found it largely did. Among drugs the government chose to finance, 56.5 percent showed relevant clinical benefit; among those it rejected, only 31.1 percent did. Publicly funded treatments also delivered larger survival gains—4.9 months on average—compared to rejected ones at 2.9 months. Yet even this positive alignment carried a shadow: 43.5 percent of publicly funded drugs failed to meet the threshold for meaningful clinical benefit.

The research exposed another gap that oncologists have long flagged. Quality of life—how a patient actually feels while undergoing treatment—was measured as a primary outcome in fewer than four in ten drug trials. It improved in just one in ten cases. This reflects how clinical trials are designed and what they measure, a point César Rodríguez, vice president of Spain's Medical Oncology Society, acknowledged. Older trials simply did not collect quality-of-life data, which now penalizes them on modern evaluation scales. But the real issue, he argued, is establishing pathways for drugs with clear, proven clinical benefit to reach patients faster.

The pharmaceutical industry countered with its own numbers. A Columbia University researcher found that new cancer treatments extended life expectancy for Spanish cancer patients by 2.77 years between 1999 and 2016. Spain's Medical Oncology Society reported that five-year survival rates improved slightly between 2016 and 2021, rising from 52 percent to 55 percent in men and 59 percent to 62 percent in women. Yet in those same five years, spending on cancer treatments in Spain doubled to 3.11 billion euros. Josep Tabernero, director of the Vall d'Hebron Institute of Oncology, argued that the solution lies in two directions: stronger evaluation frameworks and more flexible pricing. A single global price for a drug makes no sense, he contended, when the same medication has different effects depending on the stage of disease, the patient's circumstances, and the country's resources. Modern data tools now make it possible to measure what value a drug delivers to each patient and price accordingly.

Spain introduced outcome-based payment agreements in 2019, where the government pays the full cost of a treatment only if it meets agreed clinical targets. But fewer than a dozen drugs use this model so far. Eduardo López Briz, who coordinates the Genesis drug evaluation group at Spain's Hospital Pharmacy Society, summed up the challenge: the country must choose whether to see the glass as half full or half empty, but either way, it needs to move toward better use of public resources. That requires building a solid evaluation structure with scientific rigor at its core. The battle against cancer continues to produce small victories, but the research makes clear that Spain cannot afford to fund every victory equally.